GlaxoSmithKline beats profit forecasts despite Advair hit, lower margins
July 29, 2015 at 07:39 AM EDT
LONDON (Reuters) - A further slide in sales of lung drug Advair and lower profit margins following a business overhaul hit GlaxoSmithKline in the second quarter, although core earnings per share fell by a less than expected 9 percent.